Profitable DNA Nutrition Platform | 10,000 Users | 59% SDE Margi
Share on Facebook 
Post to X 
Share on LinkedIn 
Share on Reddit Business Description
PROFITABLE DNA NUTRITION PLATFORM, 10,000 USERS, 59% SDE MARGIN
A profitable, founder-built precision-nutrition platform that has sold its core product every day for eight years.
The company translates a customer's DNA into a practical, personalized way of eating. A proprietary algorithm classifies each customer into one of twenty named diet types, then generates a personalized meal plan and nutrition protocol built around how that individual actually metabolizes fat, carbohydrate, protein, caffeine, histamine, and dietary cholesterol. On top of that core sits a growing library of premium health reports — cardiovascular, methylation, micronutrient, longevity, sleep, and more — sold as an annual membership currently held by approximately 1,000 members, plus a branded supplement line matched to the genetic results.
This is a product with demonstrated durable product-market fit. It launched in 2018, has served thousands of customers, and has generated revenue continuously since. The twenty-diet-type framework is what customers connect with, talk about, and return for: an identity and a plan rather than a raw data dump. Customer acquisition runs on SEO, organic search, email, and word of mouth, supported by HSA/FSA eligibility and inbound demand from clinics and integrative-medicine practitioners.
The business is profitable and capital efficient. Revenue grew from under $60,000 to $555,300 in three years while remaining profitable every year. In 2025 it generated $327,200 in seller's discretionary earnings — a 59% SDE margin — on a fully remote operation with no full-time employees and approximately 79% gross margins.
The platform has also proven it can extend. A 2025 supplement line and a 2026 environmental-genomics release were both built and shipped on modest budgets using the existing architecture, and a consented research cohort has been accumulating alongside the core business. These represent optionality on top of a proven cash-generating core.
Highlights:
$555,300 revenue in 2025 | $327,200 SDE | ~79% gross margins
Eight consecutive years of sales on the core DNA nutrition product, launched 2018
~110% three-year revenue CAGR (FY22 $58.5K → FY25 $555.3K); SDE up from $29.9K to $327.2K
Proprietary twenty-diet-type taxonomy built on 200+ vetted genetic factors, each carrying an internal Science Grade derived from a two-year peer-reviewed literature review
AI engine generating personalized meal plans and nutrition protocols directly from genetic results
Approximately 1,000 members paying annual fees — an established subscription layer built without a dedicated conversion program
Two acquisition paths into the core product: physical test kits fulfilled through a CLIA-certified lab, and near-zero-COGS analysis of raw data uploaded from 23andMe and Ancestry
2025 supplement line with repeat-purchase behavior
Demonstrated B2B demand from wellness clinics, IV clinics, functional-medicine providers, and physicians
Strong SEO, low CAC, HSA/FSA eligible
Lean and remote: owner part-time plus four independent contractors, no physical overhead
Consented, transferable genome + environment research dataset — a monetization path not yet activated
A profitable, founder-built precision-nutrition platform that has sold its core product every day for eight years.
The company translates a customer's DNA into a practical, personalized way of eating. A proprietary algorithm classifies each customer into one of twenty named diet types, then generates a personalized meal plan and nutrition protocol built around how that individual actually metabolizes fat, carbohydrate, protein, caffeine, histamine, and dietary cholesterol. On top of that core sits a growing library of premium health reports — cardiovascular, methylation, micronutrient, longevity, sleep, and more — sold as an annual membership currently held by approximately 1,000 members, plus a branded supplement line matched to the genetic results.
This is a product with demonstrated durable product-market fit. It launched in 2018, has served thousands of customers, and has generated revenue continuously since. The twenty-diet-type framework is what customers connect with, talk about, and return for: an identity and a plan rather than a raw data dump. Customer acquisition runs on SEO, organic search, email, and word of mouth, supported by HSA/FSA eligibility and inbound demand from clinics and integrative-medicine practitioners.
The business is profitable and capital efficient. Revenue grew from under $60,000 to $555,300 in three years while remaining profitable every year. In 2025 it generated $327,200 in seller's discretionary earnings — a 59% SDE margin — on a fully remote operation with no full-time employees and approximately 79% gross margins.
The platform has also proven it can extend. A 2025 supplement line and a 2026 environmental-genomics release were both built and shipped on modest budgets using the existing architecture, and a consented research cohort has been accumulating alongside the core business. These represent optionality on top of a proven cash-generating core.
Highlights:
$555,300 revenue in 2025 | $327,200 SDE | ~79% gross margins
Eight consecutive years of sales on the core DNA nutrition product, launched 2018
~110% three-year revenue CAGR (FY22 $58.5K → FY25 $555.3K); SDE up from $29.9K to $327.2K
Proprietary twenty-diet-type taxonomy built on 200+ vetted genetic factors, each carrying an internal Science Grade derived from a two-year peer-reviewed literature review
AI engine generating personalized meal plans and nutrition protocols directly from genetic results
Approximately 1,000 members paying annual fees — an established subscription layer built without a dedicated conversion program
Two acquisition paths into the core product: physical test kits fulfilled through a CLIA-certified lab, and near-zero-COGS analysis of raw data uploaded from 23andMe and Ancestry
2025 supplement line with repeat-purchase behavior
Demonstrated B2B demand from wellness clinics, IV clinics, functional-medicine providers, and physicians
Strong SEO, low CAC, HSA/FSA eligible
Lean and remote: owner part-time plus four independent contractors, no physical overhead
Consented, transferable genome + environment research dataset — a monetization path not yet activated
About the Business
- Years in Operation
- 8
- Facilities & Assets
- The company was built science-first. Before launch, the founding team — led by a head of research and lead geneticist — spent the better part of two years reviewing hundreds of peer-reviewed studies on genetics and nutrition, ranking genes by scientific validation and assigning each an internal Science Grade. That research became the backbone of the nutrition algorithm and the twenty-diet-type framework.
The product launched in 2018 anchored on a central scientific question: why do people respond so differently to the same foods — for example, large versus negligible LDL changes on the same saturated-fat intake? Eight years later, that question still drives the roadmap. The company has since layered a premium health-report membership, a supplement line, and an environmental-genomics module onto the same core platform, each reusing the existing infrastructure rather than requiring a rebuild. - Market Outlook / Competition
- Business is positioned well to be a serious competitor in the space.
Eight years of proven demand, not a launch story. The core product has sold continuously since 2018 and has personalized nutrition for thousands of customers. This is not a business asking a buyer to underwrite an unproven thesis — the demand is established, measured, and repeatable.
A framework customers actually love. The twenty diet types give an abstract genetic result a name, a personality, and a meal plan. That is why the product retains attention in a category where most competitors deliver a PDF the customer reads once. It supports word-of-mouth acquisition, repeat purchase into the membership tier, and a low blended customer acquisition cost.
Profitable and growing — rare in consumer genomics. Most companies in this category burn cash. This one has compounded revenue and earnings together to a 59% SDE margin while fully self-funded. - Opportunities for Growth
- Expand the supplement line and complete the Amazon marketplace launch. The core analysis already tells every customer which supplements matter for them; the fulfillment of that recommendation is currently mostly unmonetized. This is the seller's view of the nearest-term opportunity.
• Push the raw-data upload channel. Millions of consumers hold 23andMe and Ancestry data with no ongoing use for it. This channel carries near-zero COGS and is undermarketed.
About the Sale
- Seller Motivation
- Other Personal Interests
Listing Info
- ID
- 2536321
- Listing Views
Listing ID: 2536321 The information on this listing has been provided by either the seller or a business broker representing the seller. BizQuest has no interest or stake in the sale of this business and has not verified any of the information and assumes no responsibility for its accuracy, veracity, or completeness. See our full Terms of Use. Learn how to avoid scams.
Similar Listings
